Injection training for the 2026 at-home Leqembi regimen means a clinician walks you through using the Leqembi Iqlik autoinjector before you ever inject at home, and you practice until the motions are automatic. Leqembi (lecanemab-irmb) is an anti-amyloid antibody for early Alzheimer's disease, and its subcutaneous autoinjector is now approved for both starting and maintenance dosing, which means most of the preparation work happens before the first home injection rather than during it. The FDA approved the Leqembi Iqlik autoinjector for once-weekly 360 mg maintenance dosing in August 2025, for patients who had already completed 18 months of biweekly IV lecanemab, according to Eisai and Biogen's approval announcement. In July 2026 the FDA extended that approval to a subcutaneous starting dose, letting newly eligible patients begin lecanemab at home instead of starting with IV infusions, as reported by Drug Topics.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the At-Home Regimen Actually Involves
- What Happens Before the First Home Injection
- Why MRI Monitoring Still Matters With Home Dosing
- What Changes With Subcutaneous Dosing — and What Doesn't
- Frequently Asked Questions
What the At-Home Regimen Actually Involves
The starting-dose regimen is 500 mg given once weekly as two separate 250 mg autoinjector doses, each taking about 15 seconds to deliver, per Drug Topics' coverage of the July 2026 approval. Once a patient has built up enough drug in the body, the regimen shifts to maintenance dosing: a single weekly 360 mg injection in 1.8 mL, also delivered in roughly 15 seconds through the same autoinjector device. Both doses go into the skin rather than a vein, which is what makes home administration possible at all.
Eisai has described the autoinjector as the first anti-amyloid Alzheimer's therapy that a patient or caregiver can inject outside a clinic, a shift from the twice-monthly infusion visits that lecanemab originally required. For a person with mild cognitive impairment or mild dementia, the practical difference is fewer clinic trips and more responsibility placed on a caregiver or, in some cases, the patient. That shift is exactly why injection training exists as a formal, required step rather than a pamphlet handed out at pickup.
What Happens Before the First Home Injection
A clinician must provide hands-on education to the patient and caregiver before any home use begins. This is not optional reading material; it is a supervised session where someone demonstrates the injection and watches the patient or caregiver attempt it. Eisai's LEQEMBI Companion program backs this up with injection-training materials, access to nurse educators, and a tool for tracking doses once home dosing starts, according to PharmaCally's reporting on the program.
The training itself appears to work for most people. In a usability study of 50 early-Alzheimer's patients and 50 caregivers who practiced with a needle-free training version of the autoinjector, 94% rated the device easy to use afterward, as reported by Alzheimer's News Today. That high comfort rate is a reason the training model relies on hands-on practice with a non-injecting version of the device before anyone handles a real dose. A practical checklist for this stage looks like:.
- Schedule the in-person training session with the prescribing clinic before the first fill is picked up.
- Identify who will actually give the injection — the patient, a spouse, or another caregiver — and make sure that person attends training.
- Ask about the LEQEMBI Companion program's nurse-educator support line for questions that come up after training ends.
- Practice with any needle-free trainer device offered, repeating the motion until it feels routine.
- Set up the dose-tracking tool so missed or delayed doses are easy to spot.
Why MRI Monitoring Still Matters With Home Dosing
Switching to a home injection does not remove the need for brain imaging. Every patient on lecanemab, by either the IV or subcutaneous route, needs a baseline MRI and follow-up scans before the 5th, 7th, and 14th doses to check for ARIA, short for amyloid-related imaging abnormalities — brain swelling (ARIA-E) and small bleeds called microhemorrhages (ARIA-H), according to prescribing information summarized by CarelonRx. Clinical vigilance is recommended to be highest in the first 14 weeks of treatment. Genetic risk should factor into planning before the first dose.
The label recommends ApoE ε4 genotype testing before starting treatment, because ApoE ε4 homozygotes — roughly 15% of Alzheimer's patients — have substantially higher rates of symptomatic and severe ARIA, according to FDA prescribing information. Treatment can proceed without this test, but then a patient's homozygote risk status is simply unknown going in. The numbers behind that risk are specific: clinical data in the label show ARIA occurring in about 40% of ApoE ε4 homozygotes on lecanemab, compared with 21% on placebo, as reproduced by CarelonRx. Home injection training covers the mechanics of the device, but it does not replace the scheduled MRI visits that catch ARIA early — those stay on the calendar regardless of where the injection happens.
What Changes With Subcutaneous Dosing — and What Doesn't
One real advantage of the switch to subcutaneous dosing is a sharp drop in infusion-type reactions. In the Clarity AD open-label extension substudy of 49 patients who moved from IV to the autoinjector after at least 18 months of IV therapy, systemic injection-related reactions occurred in under 1% of patients on the autoinjector, compared with roughly 26% on IV infusion, according to Eisai and Biogen's press release. That difference is one of the clearest practical benefits of moving to home injection for patients who previously tolerated IV dosing poorly. What doesn't change is the underlying cost and access structure.
The autoinjector carries a wholesale acquisition cost of $375 per dose, which works out to about $19,500 a year, and it became commercially available through specialty pharmacy channels starting October 6, 2025, per the same Eisai and Biogen announcement. Specialty pharmacy distribution matters for planning, since it typically means coordinating delivery and storage logistics with that pharmacy rather than picking up the drug at a standard retail counter. Families preparing for the at-home regimen should expect the specialty pharmacy, not the prescribing clinic, to handle shipping schedules and refill timing. Building that contact into the same preparation window as injection training avoids a gap between finishing training and actually having a dose on hand to use.
Frequently Asked Questions
Does moving to home injection mean skipping brain MRIs?
No. Every patient still needs a baseline MRI and scans before the 5th, 7th, and 14th doses to check for ARIA, regardless of whether the drug is given by IV or autoinjector.
How long does each autoinjector injection take?
About 15 seconds per injection, whether it's a 360 mg maintenance dose or one of the two 250 mg starting doses given weekly.
Who is most at risk for complications on lecanemab?
ApoE ε4 homozygotes, about 15% of Alzheimer's patients, show ARIA in roughly 40% of cases on the drug versus 21% on placebo, which is why genotype testing is recommended before starting.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: A Preparation Checklist for People With Early Alzheimer’s
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: A Preparation Checklist for People With Early Alzheimer’s
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: Data Questions Family Caregivers Should Ask
